Compared side by side

BPC-157 vs larazotide: how they differ

Reviewed How we check the libraryPublished by PepVault

The short answer

Both are aimed at the gut, from different angles: larazotide is an oral drug candidate that blocks the zonulin pathway to keep the junctions between gut cells closed, and BPC-157 is a peptide that, in animal studies, protects and repairs the gut lining. Larazotide reached phase 3 trials in celiac disease but was never approved, and in its celiac trials the gut-permeability test didn’t change. Larazotide is taken by mouth 3 times a day with meals; BPC-157 is mostly injected, once or twice daily.

Side by side

ComparedBPC-157Larazotide
CategoryHealing & recoveryHealing & recovery
Also known asBody Protection Compound 157, BPC157AT-1001, Larazotide Acetate
What it isA peptide derived from a protective protein in your stomach.An oral drug candidate aimed at the 'gates' between cells in your gut lining: it blocks the zonulin pathway to keep them closed.
How it worksSynthetic pentadecapeptide derived from a protein in human gastric juice. In animal studies it promotes angiogenesis, speeds tendon, ligament and muscle healing, modulates dopamine and serotonin systems, and protects the gut lining.Tight junction regulator that blocks the zonulin pathway to reduce gut permeability; in cell and animal studies it tightens the junctions between gut cells. In human celiac trials the gut-permeability test didn't change. Phase 2 trials were run in celiac disease, and a phase 3 was stopped in 2022 after an interim analysis.
Commonly reportedFaster recovery from tendon and ligament injuries, and a calmer gut. It's one of the most widely used peptides in the community; the human studies so far are three small uncontrolled pilots.Less bloating and post-meal discomfort, though many notice little. It reached phase 3 trials in celiac disease but was never approved.
Studied rangeResearch range: 200–500 mcg. Studied in research — not a recommendation.Research range: 0.5–1 mg. Studied in research — not a recommendation.
How oftenOnce or twice daily3x daily with meals
Half-life~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes)Very short (local gut action)
RouteSubQ injection, IM injection, Oral (less studied)Oral
Typical runTypically 4–12 weeks. Many run until injury resolves then stop. Some run indefinitely at lower doses. Opinions vary widely.Typically used for 4–12 weeks alongside gut healing protocols.
EvidenceEmerging: primarily preclinical / limited human dataModerate: animal studies + some human data
Common side effectsNausea (rare), injection site irritation, vivid dreams, dizzinessGenerally well tolerated, mild GI upset, nausea

Typical run: Community practice — opinions vary. Not a clinical recommendation.

A smiling man in a grey t-shirt in his living room, holding his phone

PepVault for iPhone

Taking BPC-157 or larazotide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Week by week

Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.

BPC-157

  • Day 1–7 Week one: early hints, for some
  • Day 7–14 Pain often starts to ease
  • Day 14–21 Pain often eases by week three
  • Day 21–28 Many report a calmer gut
  • Day 28–42 The slower part of repair
  • Day 42–56 Six weeks in: taking stock
  • Day 84+ Past week 12, the data runs thin

Every card for BPC-157, with its sources

Larazotide

  • Day 1–14 Early days at the gut lining
  • Day 14–42 What users notice in weeks 2 to 6
  • Day 42–84 Taper or maintain

Every card for larazotide, with its sources

Together or one or the other

BPC-157 and larazotide are a common stack: larazotide lists BPC-157 among its common stacks.

Community · Larazotide

Gut repair trio

Three layers of the same problem: larazotide targets the gaps between gut cells, BPC-157 supports deeper repair of the gut lining, and KPV damps the inflammation in between. A common practitioner stack for gut recovery. Commonly reported: calmer digestion over several weeks.

Questions people ask

How long do BPC-157 and larazotide last?

The half-life of BPC-157 is ~4–6 hours (community estimate for SubQ; not measured in people: in rats and dogs it cleared in under 30 minutes). The half-life of larazotide is very short (local gut action).

How often are BPC-157 and larazotide taken?

BPC-157: once or twice daily. Routes: SubQ injection, IM injection, oral (less studied). Larazotide: 3x daily with meals. Route: Oral.

How are BPC-157 and larazotide dosed in research?

The research range for BPC-157 is 200–500 mcg. The research range for larazotide is 0.5–1 mg. Studied in research — not a recommendation.

What are the common side effects of BPC-157 and larazotide?

For BPC-157, the library lists: nausea (rare), injection site irritation, vivid dreams, dizziness. For larazotide: generally well tolerated, mild GI upset, nausea.

Are BPC-157 and larazotide taken together?

BPC-157 and larazotide are a common stack: larazotide lists BPC-157 among its common stacks. Three layers of the same problem: larazotide targets the gaps between gut cells, BPC-157 supports deeper repair of the gut lining, and KPV damps the inflammation in between. A common practitioner stack for gut recovery. Commonly reported: calmer digestion over several weeks.

Each one in full

Track it in the app

PepVault for iPhone

Taking BPC-157 or larazotide? Log it in PepVault

Each dose, each vial and your step-ups in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo